Viel Erika, Arbion Flavie, Barbe Catherine, Bougnoux Philippe
INSERM, U1069, Nutrition Croissance et Cancer, Faculté de Médecine, Université François-Rabelais, Tours, France.
BMC Cancer. 2014 Sep 22;14:690. doi: 10.1186/1471-2407-14-690.
Metastatic breast cancer has consistently been viewed as a non-curable disease. Specific palliative treatments such as chemotherapy and hormone therapy have resulted in a mean overall survival of approximately 30 months. While cases of prolonged complete response have been reported with hormone or trastuzumab monotherapy, rendering metastatic breast cancer a chronic disease, any treatment withdrawal has ineluctably led to relapse. Prolonged remission without any anti-cancer treatment has never been reported to our knowledge.
We report here the unique observation of the spontaneous evolution of two breast cancer patients with synchronous liver metastases who decided to stop trastuzumab after achieving complete response. They were Caucasian women with synchronous liver metastatic breast carcinoma. Both breast cancers reached skin and regional lymph nodes. There were several liver metastases in both patients. They received surgery, radiotherapy and chemotherapy combined with trastuzumab. They decided to stop their treatment, despite guidelines. After a follow-up longer than 20 months, they did not relapse clinically, radiologically, and biologically.
This findings question the belief of the unavoidability of recurrence of metastatic breast cancer, specifically in the liver. It opens up the unprecedented possibility of a cure-like state in exceptional and probably special cases.
转移性乳腺癌一直被视为一种无法治愈的疾病。化疗和激素治疗等特定姑息治疗使平均总生存期约为30个月。虽然有报道称激素或曲妥珠单抗单药治疗可出现长期完全缓解,使转移性乳腺癌成为一种慢性病,但任何治疗中断都不可避免地导致复发。据我们所知,从未有过在未进行任何抗癌治疗的情况下长期缓解的报道。
我们在此报告两例同步肝转移乳腺癌患者在达到完全缓解后决定停用曲妥珠单抗后的独特自然病程观察。她们是患有同步肝转移性乳腺癌的白人女性。两例乳腺癌均累及皮肤和区域淋巴结。两名患者均有多处肝转移。她们接受了手术、放疗、化疗以及曲妥珠单抗治疗。尽管有指南规定,她们仍决定停止治疗。经过超过20个月的随访,她们在临床、影像学和生物学方面均未复发。
这一发现对转移性乳腺癌(特别是肝转移)不可避免复发的观点提出了质疑。它为特殊且可能罕见的病例带来了类似治愈状态的前所未有的可能性。